Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SRRK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsScholar Rock resubmits FDA application for apitegromab SMA treatment, decision expected Sept 2026
Filed March 31, 2026 · Period ending March 31, 2026 · ~1 min read
Key Changes
-
high
Company resubmitted biologics license application to FDA for apitegromab to treat spinal muscular atrophy in children and adults, addressing prior regulatory feedback
Item 7.01 verify on EDGAR → -
high
FDA acceptance expected within 30 days, with six-month review period targeting regulatory decision by late September 2026
Press Release verify on EDGAR → -
high
Resubmission represents critical regulatory milestone that could enable commercial launch if approved
Item 7.01 verify on EDGAR →
Summary
Scholar Rock announced it has resubmitted its biologics license application to the FDA for apitegromab, a treatment for spinal muscular atrophy affecting both children and adults. This resubmission follows prior FDA feedback, indicating the company has addressed regulatory concerns and is advancing toward potential approval.
The FDA is expected to accept the resubmission within 30 days and complete its review by late September 2026. For retail investors, this represents a make-or-break moment for Scholar Rock's lead drug candidate. FDA approval would open the door to commercial sales and revenue generation, while rejection could significantly impact the company's valuation and future prospects.
The six-month review timeline provides a clear catalyst date. Watch for the FDA's formal acceptance notice in April 2026, which would confirm the late September target date. Any updates on manufacturing readiness or commercial preparation would signal management's confidence in approval odds.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Scholar Rock filed an 8-K to furnish a press release issued March 31, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release issued by the Company on March 31, 2026, furnished hereto.
The company furnished a press release dated March 31, 2026 as Exhibit 99.1. The 8-K body does not describe the press release content, so the nature of the disclosure cannot be determined from this filing alone.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Scholar Rock Holding Corporation (the “Company”) issued a press release announcing it resubmitted its biologics license application (“BLA”) to the U.S. Food and Drug Administration (the “FDA”) for apitegromab for the treatment of children and adults with spinal muscular atrophy (“SMA”).
The company has resubmitted its biologics license application to the FDA for apitegromab, a drug candidate for treating spinal muscular atrophy in both children and adults. This resubmission suggests the company previously received feedback from the FDA and has now addressed those issues, moving the drug candidate forward in the regulatory approval process.
Event · Item 8.01 — Other Events
Scholar Rock resubmitted its BLA to FDA for apitegromab for SMA treatment, expecting acceptance within 30 days and PDUFA date in late Sept 2026.
Added in current filing · verify on EDGAR →
On March 31, 2026, the Company announced that it resubmitted its BLA to the FDA for apitegromab for the treatment of children and adults with SMA. The Company anticipates FDA acceptance within 30 days and a review period of up to six months from the date of resubmission, with a Prescription Drug User Fee Act (“PDUFA”) action date expected in late September 2026.
Scholar Rock has resubmitted its Biologics License Application to the FDA for apitegromab, a treatment for spinal muscular atrophy (SMA) in children and adults. The company expects the FDA to accept the resubmission within 30 days and complete its review within six months, targeting a regulatory decision by late September 2026. This represents a critical regulatory milestone that could enable commercial launch if approved.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify